open access

Vol 12, No 4 (2007)
Untitled
Published online: 2007-07-01
Submitted: 2006-11-29
Get Citation

Efficacy of samarium 153 and strontium 89 treatment for bone metastases in prostate cancer patients: monotherapy vs. treatment combined with external beam radiotherapy. Preliminary report

Maciej Bączyk, Piotr Milecki, Piotr Martenka, Jerzy Sowiński
DOI: 10.1016/S1507-1367(10)60059-4
·
Rep Pract Oncol Radiother 2007;12(4):211-216.

open access

Vol 12, No 4 (2007)
Untitled
Published online: 2007-07-01
Submitted: 2006-11-29

Abstract

Background

Approximately 60–80% of metastatic prostate cancer patients suffer from pain caused by bone metastases. Bone metastases have a negative impact on patient performance status.

Aim

The aim of study was to compare the efficacy of treatment with strontium 89 or samarium 153 in monotherapy vs. radioisotope treatment combined with external beam radiotherapy (EBRT) in prostate cancer patients with bone metastases.

Materials/Methods

We retrospectively analyzed one hundred (n=100) metastatic prostate cancer patients aged between 53 and 84 years, who we divided into four treatment groups: 30 pts received Sr-89 monotherapy; 30 patients received Sm-153 monotherapy; 20 pts received Sr-89 combined with EBRT; and 20 pts received Sm-153 combined with EBRT. Follow-up was 4 months. All patients prior to therapy had their bone metastases confirmed by bone scan examination. Pathologic fractures were excluded and the nature of metastases (osteoblastic/mixed) was evaluated with X-ray films and/or CT and/or MRI. Sr-89 therapy consisted of a standard dose of 150MBq, while Sm-153 was administered proportionally to body weight (37MBq/kg). In combined treatment groups EBRT was given to the dominant metastatic site with 8Gy in one fraction or 20Gy in five daily fractions. Treatment efficacy was determined by change in pain intensity evaluated according to visual analogue scale (VAS), changes in Karnofsky performance status (KPS) and in the use of analgesics.

Results

Complete pain relief (VAS<3) was observed in 33% and 40% of patients in Sr-89 and Sm-153 monotherapy groups and in 50% and 60% of patients treated with Sr-89 and Sm-153 therapy combined with EBRT, respectively. Unsatisfactory response to treatment (VAS>5) was noted in 20% of patients in both monotherapy groups and in 10% and 15% of patients in Sm-153 and Sr-89 combined with EBRT, respectively. Decrease in pain intensity and in the use of analgesics as well as improvement in performance status were statistically significant for combined therapy vs. monotherapy (p<0.05). Treatment was well tolerated, with 3 patients suffering from severe pancytopenia and 22 patients with mild leucopenia and/or thrombocytopenia.

Conclusions

Radioisotope therapy with Sr-89 or Sm-153 combined with external beam radiotherapy in comparison with radioisotope monotherapy improves efficacy of treatment. Treatment toxicity is low.

Abstract

Background

Approximately 60–80% of metastatic prostate cancer patients suffer from pain caused by bone metastases. Bone metastases have a negative impact on patient performance status.

Aim

The aim of study was to compare the efficacy of treatment with strontium 89 or samarium 153 in monotherapy vs. radioisotope treatment combined with external beam radiotherapy (EBRT) in prostate cancer patients with bone metastases.

Materials/Methods

We retrospectively analyzed one hundred (n=100) metastatic prostate cancer patients aged between 53 and 84 years, who we divided into four treatment groups: 30 pts received Sr-89 monotherapy; 30 patients received Sm-153 monotherapy; 20 pts received Sr-89 combined with EBRT; and 20 pts received Sm-153 combined with EBRT. Follow-up was 4 months. All patients prior to therapy had their bone metastases confirmed by bone scan examination. Pathologic fractures were excluded and the nature of metastases (osteoblastic/mixed) was evaluated with X-ray films and/or CT and/or MRI. Sr-89 therapy consisted of a standard dose of 150MBq, while Sm-153 was administered proportionally to body weight (37MBq/kg). In combined treatment groups EBRT was given to the dominant metastatic site with 8Gy in one fraction or 20Gy in five daily fractions. Treatment efficacy was determined by change in pain intensity evaluated according to visual analogue scale (VAS), changes in Karnofsky performance status (KPS) and in the use of analgesics.

Results

Complete pain relief (VAS<3) was observed in 33% and 40% of patients in Sr-89 and Sm-153 monotherapy groups and in 50% and 60% of patients treated with Sr-89 and Sm-153 therapy combined with EBRT, respectively. Unsatisfactory response to treatment (VAS>5) was noted in 20% of patients in both monotherapy groups and in 10% and 15% of patients in Sm-153 and Sr-89 combined with EBRT, respectively. Decrease in pain intensity and in the use of analgesics as well as improvement in performance status were statistically significant for combined therapy vs. monotherapy (p<0.05). Treatment was well tolerated, with 3 patients suffering from severe pancytopenia and 22 patients with mild leucopenia and/or thrombocytopenia.

Conclusions

Radioisotope therapy with Sr-89 or Sm-153 combined with external beam radiotherapy in comparison with radioisotope monotherapy improves efficacy of treatment. Treatment toxicity is low.

Get Citation

Keywords

prostate cancer; bone metastases; radioisotope therapy; radiotherapy

About this article
Title

Efficacy of samarium 153 and strontium 89 treatment for bone metastases in prostate cancer patients: monotherapy vs. treatment combined with external beam radiotherapy. Preliminary report

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 12, No 4 (2007)

Pages

211-216

Published online

2007-07-01

DOI

10.1016/S1507-1367(10)60059-4

Bibliographic record

Rep Pract Oncol Radiother 2007;12(4):211-216.

Keywords

prostate cancer
bone metastases
radioisotope therapy
radiotherapy

Authors

Maciej Bączyk
Piotr Milecki
Piotr Martenka
Jerzy Sowiński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl